# Ignacio Rodriguez, MD Vice President, Global Head Medical Safety Patient Safety & Pharmacovigilance Global Drug Development Novartis Pharmaceuticals Corporation

Email: ignacio.rodriguez@novartis.com

# **Education/ Professional training**

1983-1989, Doctor in Medicine and General Surgery, Javeriana University, Bogotá, Colombia.

Rotatory Internship, Hospital Regional de Villavicencio – Jan. to June 1989 (Villavicencio, Colombia). Hospital Universitario de San Ignacio – July to Dec. 1989 (Bogotá, Colombia).

1992-1995, Internal Medicine. Javeriana University, Bogotá, Colombia.

Visiting Fellow in Cardiology (Arrhythmia and Echocardiography) and Infectious Diseases, Georgetown University Medical Center, Washington, DC. - 1995

1997-1999, Clinical Pharmacology Fellowship Georgetown University Medical Center, Washington, DC.

# **Summary of Professional Achievements**

Physician scientist with more than 20 years of experience in clinical safety and risk management; wide pharmaceutical experience with small and large molecules in most Therapeutic Areas. Proven record to translate preclinical and clinical data into effective risk management strategies. Clear interest in drug-induced disease, and career progression with increased levels of complexity, responsibility, and accountability in drug development. In addition, medical expert in cardiovascular safety and past chair of the Cardiovascular Safety Research Consortium a Public Private Partnership that includes a wide variety of members from industry, regulators (FDA, MHRA, PMDA and Health Canada), and academia.

Current position with global responsibility for the Medical Safety organization across Novartis franchises and divisions worldwide, with ~ 200 associates, spanning all therapeutic areas including early and late compounds. Contributed to pave the way for Medical Safety of the future, as a key driver of clinical safety aspects in all phases of drug development.

Academic training in Internal Medicine and Clinical Pharmacology, and clinical research in cardiovascular disease with emphasis in evaluation of drug-induced effects. Early professional life in clinical practice and academic teaching/research. Clinical development experience in all phases of drug development.

Management experience with direct reports and in a matrix environment.

## **Work Experience**

## May 2019 to Present

Novartis Patient Safety & Pharmacovigilance - East Hanover, NJ

2019 Head Patient Safety, Immunology, Hepatology & Dermatology

2021 - Present Vice President, Global Head Medical Safety

2024 - Present US Food and Drug Administration (FDA) Drug Safety and Risk Management

Advisory Committee (Industry Representative)

## April 2018 to May 2019

<u>CSL Behring Global Clinical Safety and Pharmacovigilance – King of Prussia, PA</u> Therapeutic Area Head in Coagulation, Devices and Special Products.

## August 2005 to April 2018

Roche Drug Safety Risk Management - Licensing and Early Development

- 2005 Drug Safety Physician. Roche Palo Alto, CA
- 2009 Safety Science Leader. Genentech, South San Francisco, CA
- 2010 Safety Science Leader. Hoffmann-La Roche. Nutley, NJ
- 2011 Senior Safety Science Leader. Hoffmann-La Roche. Nutley, NJ, and New York, NY 2014 - Local Administrative Manager and Pharma Development Safety Site Head Roche Innovation Center New York, NY
  - 2015 Global Pharma Development Site Head Roche Innovation Center New York, NY

## April 2001 to July 2005

# Pfizer Global Research & Development

- 2001 Associate Director Clinical Research Scientist Clinical Sciences. Groton, CT.
- 2002 Associate Director Global Safety Leader Clinical Safety & Risk Management. New London, CT.
- 2004 Director Risk Management Leader Safety & Risk Management. New London, CT.

## February 1999 to March 2001

<u>University of Antioquia School of Medicine</u> - Departments of Internal Medicine and Pharmacology. Medellín, Colombia.

<u>Clínica Soma</u> - Private Practice in Internal Medicine and Clinical Pharmacology. Medellín, Colombia.

## January 1997 to January 1999

Fellowship in Clinical Pharmacology, Georgetown University Medical Center. Washington, DC. (Award from Merck Sharp & Dohme International). Main activities included: clinical research in cardiovascular pharmacology, and clinical practice in the Clinical Pharmacology consult service at Georgetown University Hospital.

## February 1996 to January 1997

<u>Hospital General de Medellin, & Hospital Pablo Tobón Uribe</u> - Internal Medicine attending and teaching. Medellín, Colombia.

<u>Clínica León XIII</u>, National Medical Service, Internal Medicine attending and Cardiovascular Risk Program Director. Medellín, Colombia.

## January 1995 to January 1996

Clínica Bochica (Private Clinic), Assistant Medical Director. Bogotá, Colombia.

#### October 1990 to June 1992

Clínica de Marly (Private Clinic), surgery assistant. Bogotá, Colombia.

<u>Clínica del Country</u> (Private Clinic), general practitioner: hospitalist, surgery assistant and emergency room MD. Bogotá, Colombia.

## March 1990 to September 1990

<u>Ecopetrol</u> - Medical rural work, (Compulsory social service as a general practitioner). Barrancabermeja, Colombia.

## **Publications**

Available upon request